Vitamin E supplements can significantly reduce the risk of heart attacks and related deaths for diabetics who carry a particular version of a gene, according to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel.
After 18 months of treatment, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units of vitamin E daily had more than 50% fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene. The researchers presented the results at the American Heart Meetings in Orlando, Florida, last month. The full study appeared in the November 21 on-line edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology.
Most of the difference came from the reduced number of heart attacks among those taking vitamin E. In the group of 1,434 Hp 2-2 individuals taking part in the study, seven people had a heart attack, compared to 17 who did not take the vitamin. Andrew Levy, of the Technion Faculty of Medicine, said there were no side effects observed in patients who did take vitamin E.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze